The global market for lentiviral vector contract development and manufacturing organizations is anticipated to register significant growth over the forecast period. Lentiviral vectors (LVs) are increasingly in demand as a means of ex vivo gene delivery due to the expansion of cell and gene therapy and the advent of CAR-T treatments. In comparison to other vectors, they have a number of benefits for gene therapy applications, such as long-term transgene expression in target cells, minimal immunogenic potential, and the ability to transduce both dividing and non-dividing cells. Thus, the number of clinical trials utilizing LVs for gene delivery has been rising globally because of these benefits.
The COVID-19 pandemic increased research efforts to find an effective treatment for the infection. The urgent need for vaccine research because of the pandemic impelled the market's growth. Various companies initiated R&D of lentiviral vector-based vaccines as a treatment option for COVID-19. For instance, in May 2022, TheraVectys announced the development of its first intranasal vaccine to fight against COVID-19, called Lenti-Covid. Lenti-COVID is given as a booster dose via the nasal method. The respiratory mucosa develops a protective immunity as a result of this intranasal booster. These findings open the door for a cutting-edge vaccination approach that will shorten the viral chain of transmission.
Based on workflow, the segment is divided into upstream and downstream processing. With downstream processing dominating the market, it is also anticipated to grow at the fastest CAGR during the forecast period. The dominance of the downstream segment is a result of rising investment in the treatment of viral diseases and biologics, as well as rising demand for lentiviral vectors in vaccine development.
The North Americ region is expected to dominate the market over the forecast period due to increasing research advancements in gene therapy, rising research by academic institutes for the development of new vaccines using lentivirus, and the presence of major market players offering lentiviral vector contract development and manufacturing services in the region.
The key market players include Thermo Fischer Scientific, Inc., Oxford Biomedica, Charles River Laboratories International, Inc., Creative Biogene, GenScript ProBio, Merck KGaA, Catalent Inc., Ask Bio, Lonza, and Curia Global, Inc. They are adopting various strategies like expansions, partnerships, collaborations, mergers and acquisitions. For instance, In July 2022, Oxford Biomedica announced signing of a Licence and Supply Agreement with a private biotechnology company that is based in U.S. The LSA offers the U.S. based company a non-exclusive licence to use Oxford Biomedica's LentiVector platform for their CAR-T product and establishes a three-year Clinical Supply Agreement.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."